Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

Background Ustekinumab targets interleukin (IL)-12 and IL-23 in the treatment of moderate-to-severe psoriasis. Objective To evaluate overall pooled study data to assess the safety profile of ustekinumab through 3 years of treatment. Methods Cumulative safety data were pooled from studies in 3117 ust...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Academy of Dermatology 2012-05, Vol.66 (5), p.731-741
Hauptverfasser:	Lebwohl, Mark, MD, Leonardi, Craig, MD, Griffiths, Christopher E.M., MD, Prinz, Jörg C., MD, Szapary, Philippe O., MD, MSCE, Yeilding, Newman, MD, Guzzo, Cynthia, MD, Li, Shu, MS, Hsu, Ming-Chun, PhD, Strober, Bruce, MD, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult adverse events Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Dermatology Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Drug-Related Side Effects and Adverse Reactions Etanercept Evaluation Studies as Topic Female Follow-Up Studies Humans Immunoglobulin G - adverse effects Immunoglobulin G - therapeutic use long-term safety Male Medical sciences Middle Aged moderate-to-severe psoriasis Psoriasis - diagnosis Psoriasis - drug therapy Psoriasis. Parapsoriasis. Lichen Receptors, Tumor Necrosis Factor - therapeutic use Risk Assessment Safety Management serious adverse events Severity of Illness Index Time Factors Treatment Outcome Ustekinumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!